The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial

IKZF1 gene deletion is an indicator of poor prognosis in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). The AEIOP/BFM group proposed that the prognostic strength of IKZF1 deletion could be remarkably improved by taking into account additional genetic deletions and reported that among patients with an IKZF1 deletion those with deletions in CDKN2A/2B, PAX5, or PAR1 in the absence of ERG deletion, grouped as IKZF1plus, had the worst outcome.

[1]  Stephanie Vairy,et al.  IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly. , 2020, Blood reviews.

[2]  H. Cavé,et al.  IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? , 2019, Blood.

[3]  H. Cavé,et al.  Relevant subtypes in childhood ALL , 2019, HemaSphere.

[4]  D. Steinemann,et al.  IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Clappier,et al.  IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951 , 2015, Leukemia.

[6]  B. Meissner,et al.  ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia , 2015, Leukemia.

[7]  P. Brown,et al.  Treatment of pediatric acute lymphoblastic leukemia. , 2015, Pediatric clinics of North America.

[8]  L. Silverman.  Balancing cure and long-term risks in acute lymphoblastic leukemia. , 2014, Hematology. American Society of Hematology. Education Program.

[9]  H. Cavé,et al.  Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial , 2014, Haematologica.

[10]  F. Speleman,et al.  Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. , 2013, Blood.

[11]  K. Ness,et al.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health , 2011, Expert review of hematology.

[12]  Y. Bertrand,et al.  Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. , 2010, Blood.

[13]  R. Foà,et al.  IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[15]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[16]  H. Cavé,et al.  A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia , 2002, Leukemia.

[17]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[18]  F. Sigaux,et al.  An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions , 2014, Leukemia.

[19]  B. Meissner,et al.  ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia , 2014, Leukemia.

[20]  H. Cavé,et al.  The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. , 2006, Haematologica.

[21]  J. Downing,et al.  Pediatric acute lymphoblastic leukemia. , 2003, Hematology. American Society of Hematology. Education Program.

[22]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .